- Previous Close
0.0000 - Open
0.2021 - Bid 0.2031 x --
- Ask 0.5080 x --
- Day's Range
0.2021 - 0.2021 - 52 Week Range
0.1270 - 0.5320 - Volume
23 - Avg. Volume
29 - Market Cap (intraday)
1.059M - Beta (5Y Monthly) -1.47
- PE Ratio (TTM)
0.26 - EPS (TTM)
0.7680 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CYduct Diagnostics, Inc., a healthcare instrument company, develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of disease and medical conditions. The company's products include breast endoscopy systems; 3-chip and 1-chip camera systems; cameras and accessories; endoscopic instruments, such as dissectors, graspers, scissors, needle holders, fan retractors, cautery instruments, and insufflation needles; and illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps. It also offers insufflators; laparoscopic instruments, such as general surgery, lymphadenectomy, gynecology, and thorascopy instruments; rigid scopes and accessories, including laparoscopes, operative scopes, cystoscopes, and scope trays; trocar and cannula sets, cannulas, trocars, reducer sleeves, and seals; video carts; instrument handles that include insulated handles and non-insulated handles; and veterinary instrumentation. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was founded in 1986 and is based in Westport, Connecticut.
cyductdx.comRecent News: CYDX
View MorePerformance Overview: CYDX
Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYDX
View MoreValuation Measures
Market Cap
1.06M
Enterprise Value
1.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
39.59%
Return on Assets (ttm)
-13.61%
Return on Equity (ttm)
8.39%
Revenue (ttm)
344.78k
Net Income Avi to Common (ttm)
136.51k
Diluted EPS (ttm)
0.7680
Balance Sheet and Cash Flow
Total Cash (mrq)
13.33k
Total Debt/Equity (mrq)
8.82%
Levered Free Cash Flow (ttm)
-541.37k